Transperineal template-guided prostate biopsy for patients with persistently elevated PSA and multiple prior negative biopsies.
Adjuvant radiation therapy for early stage seminoma: proton versus photon planning comparison and modeling of second cancer risk.
Radiother Oncol., Apr;103(1):12-7 (2012)
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer.
J. Clin. Oncol., Sep;30(25):3071-6 (2012)
Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer.
Int. J. Radiat. Oncol. Biol. Phys., Feb;82(2):e201-9 (2012)
Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
Eur. Urol., Apr;61(4):705-11 (2012)
Bladder preservation: optimizing radiotherapy and integrated treatment strategies.
BJU Int., Nov;102(9 Pt B):1345-53 (2008)
Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
Urology., Apr;73(4):833-7 (2009)
The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-GuÃ©rin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
BJU Int., Jul;104(2):179-83 (2009)
Proton radiation for localized prostate cancer.
Nat Rev Urol., Jun;6(6):324-30 (2009)
Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy.
Clin Imaging., 33(4):301-5 (2009)
Life, liberty, and the pursuit of protons: an evidence-based review of the role of particle therapy in the treatment of prostate cancer.
Cancer J., 15(4):312-8 (2009)
Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09.
J. Clin. Oncol., Mar;28(7):1106-11 (2010)
Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.
Cancer., May;112(10):2188-94 (2008)
Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial.
Int. J. Radiat. Oncol. Biol. Phys., Nov;78(4):1081-5 (2010)
Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention?
BJU Int., May;107(10):1582-6 (2011)
Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12.
Int. J. Radiat. Oncol. Biol. Phys., Nov;81(4):1005-9 (2011)
Interfractional variations in the setup of pelvic bony anatomy and soft tissue, and their implications on the delivery of proton therapy for localized prostate cancer.
Int. J. Radiat. Oncol. Biol. Phys., Jul;80(3):928-37 (2011)
Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis.
Int. J. Radiat. Oncol. Biol. Phys., Jan;82(1):e25-31 (2012)
Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison.
Int. J. Radiat. Oncol. Biol. Phys., Oct;69(2):444-53 (2007)
High-dose external beam radiation for localized prostate cancer: current status and future challenges.
Cancer J., 13(5):295-301 (2007)